202 related articles for article (PubMed ID: 26505625)
1. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.
Hakimi AA; Ostrovnaya I; Jacobsen A; Susztak K; Coleman JA; Russo P; Winer AG; Mano R; Sankin AI; Motzer RJ; Voss MH; Offit K; Purdue M; Pomerantz M; Freedman M; Choueiri TK; Hsieh JJ; Klein RJ
Cancer; 2016 Feb; 122(3):402-10. PubMed ID: 26505625
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.
Schutz FA; Pomerantz MM; Gray KP; Atkins MB; Rosenberg JE; Hirsch MS; McDermott DF; Lampron ME; Lee GS; Signoretti S; Kantoff PW; Freedman ML; Choueiri TK
Lancet Oncol; 2013 Jan; 14(1):81-7. PubMed ID: 23219378
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
4. Commentary on "Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study." Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK, Dana-Farber Cancer Institute, Boston, MA 02115.: Lancet Oncol 2013;14(1):81-87. [Epub 2012 Dec 7]. doi: 10.1016/S1470-2045(12)70517-X. Erratum in, Lancet Oncol 2013;14(3):e89.
Meng M
Urol Oncol; 2014 May; 32(4):512-3. PubMed ID: 24767687
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of single-nucleotide polymorphism signature for recurrence in localised renal cell carcinoma: a retrospective analysis and multicentre validation study.
Wei JH; Feng ZH; Cao Y; Zhao HW; Chen ZH; Liao B; Wang Q; Han H; Zhang J; Xu YZ; Li B; Wu JT; Qu GM; Wang GP; Liu C; Xue W; Liu Q; Lu J; Li CX; Li PX; Zhang ZL; Yao HH; Pan YH; Chen WF; Xie D; Shi L; Gao ZL; Huang YR; Zhou FJ; Wang SG; Liu ZP; Chen W; Luo JH
Lancet Oncol; 2019 Apr; 20(4):591-600. PubMed ID: 30880070
[TBL] [Abstract][Full Text] [Related]
6. Higher expression of topoisomerase II alpha is an independent marker of increased risk of cancer-specific death in patients with clear cell renal cell carcinoma.
Parker AS; Eckel-Passow JE; Serie D; Hilton T; Parasramka M; Joseph RW; Wu KJ; Cheville JC; Leibovich BC
Eur Urol; 2014 Nov; 66(5):929-35. PubMed ID: 24388441
[TBL] [Abstract][Full Text] [Related]
7. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
8. Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems.
Verine J; Colin D; Nheb M; Prapotnich D; Ploussard G; Cathelineau X; Desgrandchamps F; Mongiat-Artus P; Feugeas JP
Am J Surg Pathol; 2018 Apr; 42(4):423-441. PubMed ID: 29356723
[TBL] [Abstract][Full Text] [Related]
9. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
[TBL] [Abstract][Full Text] [Related]
10. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling.
Lane BR; Li J; Zhou M; Babineau D; Faber P; Novick AC; Williams BR
J Urol; 2009 Feb; 181(2):849-60. PubMed ID: 19095258
[TBL] [Abstract][Full Text] [Related]
11. Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma.
Manley BJ; Zabor EC; Casuscelli J; Tennenbaum DM; Redzematovic A; Becerra MF; Benfante N; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Ogawa S; Arcila ME; Voss MH; Feldman DR; Coleman JA; Reuter VE; Motzer RJ; Russo P; Hsieh JJ; Hakimi AA
Eur Urol Focus; 2017 Oct; 3(4-5):421-427. PubMed ID: 28753773
[TBL] [Abstract][Full Text] [Related]
12. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
[TBL] [Abstract][Full Text] [Related]
13. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
14. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
[TBL] [Abstract][Full Text] [Related]
16. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
18. Tumor miR-125b predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
Fu Q; Liu Z; Pan D; Zhang W; Xu L; Zhu Y; Liu H; Xu J
Cancer Sci; 2014 Nov; 105(11):1427-34. PubMed ID: 25155155
[TBL] [Abstract][Full Text] [Related]
19. Development of prognostic signature based on RNA binding proteins related genes analysis in clear cell renal cell carcinoma.
Chen Q; Li ZL; Fu SQ; Wang SY; Liu YT; Ma M; Yang XR; Xie WJ; Gong BB; Sun T
Aging (Albany NY); 2021 Jan; 13(3):3926-3944. PubMed ID: 33461173
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.
El-Mokadem I; Fitzpatrick J; Bondad J; Rauchhaus P; Cunningham J; Pratt N; Fleming S; Nabi G
Br J Cancer; 2014 Sep; 111(7):1381-90. PubMed ID: 25137021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
